Filtered By:
Source: Oncology Reports
Cancer: Lung Cancer

This page shows you your search results in order of date.

Order by Relevance | Date

Total 39 results found since Jan 2013.

EHF enhances malignancy by modulating AKT and MAPK/ERK signaling in non ‑small cell lung cancer cells
Oncol Rep. 2021 Jun;45(6):102. doi: 10.3892/or.2021.8053. Epub 2021 Apr 28.ABSTRACTOverexpression of ETS‑homologous factor (EHF) in non‑small cell lung cancer (NSCLC) is associated with poor patient prognosis. To explore the mechanism of the effect of EHF in NSCLC, EHF expression was examined in NSCLC and its role in cell proliferation, invasion, cell cycle, and apoptosis of NSCLC cells was evaluated by overexpressing EHF and/or knocking down EHF expression in NSCLC cells in vitro and in cancer cell grafted mice in vivo. The results revealed that the knockdown of EHF expression in NSCLC with siRNA significantly inhibit...
Source: Oncology Reports - April 28, 2021 Category: Cancer & Oncology Authors: Lei Gao Tian Yang Shuo Zhang Yiqian Liang Puyu Shi Hui Ren Peng Hou Mingwei Chen Source Type: research

MicroRNA ‑92a promotes cell proliferation, migration and survival by directly targeting the tumor suppressor gene NF2 in colorectal and lung cancer cells.
MicroRNA‑92a promotes cell proliferation, migration and survival by directly targeting the tumor suppressor gene NF2 in colorectal and lung cancer cells. Oncol Rep. 2019 Feb 19;: Authors: Alcantara KMM, Garcia RL Abstract Inactivation of the tumor suppressor protein Merlin leads to the development of benign nervous system tumors in neurofibromatosis type2 (NF2). Documented causes of Merlin inactivation include deleterious mutations in the encoding neurofibromin2 gene (NF2) and aberrant Merlin phosphorylation leading to proteasomal degradation. Rare somatic NF2 mutations have also been detected in com...
Source: Oncology Reports - March 4, 2019 Category: Cancer & Oncology Tags: Oncol Rep Source Type: research

Upregulation and activation of p53 by erastin ‑induced reactive oxygen species contribute to cytotoxic and cytostatic effects in A549 lung cancer cells.
Upregulation and activation of p53 by erastin‑induced reactive oxygen species contribute to cytotoxic and cytostatic effects in A549 lung cancer cells. Oncol Rep. 2018 Jul 20;: Authors: Huang C, Yang M, Deng J, Li P, Su W, Jiang R Abstract The tumour‑suppressor protein p53 is a key regulator of multiple cellular processes and exerts its tumour‑suppressor function by inducing apoptotic cell death. However, emerging evidence indicates that p53 is also involved in inducing ferroptosis, which is a unique iron‑dependent form of non‑apoptotic cell death triggered by the RAS‑selective lethal small...
Source: Oncology Reports - August 4, 2018 Category: Cancer & Oncology Tags: Oncol Rep Source Type: research

RAD52 motif ‑containing protein 1 promotes non‑small cell lung cancer cell proliferation and survival via cell cycle regulation.
This study aimed to investigate the role of RDM1 in the progression of non‑small cell lung cancer (NSCLC). We found elevated RDM1 mRNA and protein expression in NSCLC tissues and cell lines compared to levels in normal lung cells. RDM1 protein expression in lung cancer tissues was found to correlate with tumor size, histological differentiation, lymph node metastasis and tumor‑node‑metastasis (TNM) stage. Knockdown of the RDM1 gene with siRNA significantly reduced the cellular proliferation rate and increased apoptosis in the human NSCLC cell line, NCI‑H1299. Compared to wild‑type NCI‑H1299 cells, RDM1 knockdow...
Source: Oncology Reports - June 1, 2018 Category: Cancer & Oncology Tags: Oncol Rep Source Type: research

Estrogen receptor β1 activation accelerates resistance to epidermal growth factor receptor-tyrosine kinase inhibitors in non-small cell lung cancer.
In conclusion, ERβ1 was activated in EGFR-TKI secondary resistance. The downregulation of ERβ1 sensitized the cells to EGFR-TKIs. ERβ1 may be a key molecule in EGFR-TKI therapy. In addition, anti-ERβ1 treatment may reverse TKI resistance. PMID: 29328407 [PubMed - as supplied by publisher]
Source: Oncology Reports - January 14, 2018 Category: Cancer & Oncology Tags: Oncol Rep Source Type: research

Src homology phosphotyrosyl phosphatase 2 mediates cisplatin-related drug resistance by inhibiting apoptosis and activating the Ras/PI3K/Akt1/survivin pathway in lung cancer cells.
In conclusion, SHP2 is a new cisplatin resistance-related phosphatase in lung cancer, which inhibits apoptosis by activating the Ras/PI3K/Akt1/survivin signaling pathway. PMID: 29207183 [PubMed - as supplied by publisher]
Source: Oncology Reports - December 6, 2017 Category: Cancer & Oncology Tags: Oncol Rep Source Type: research

Combination treatment of FTY720 and cisplatin exhibits enhanced antitumour effects on cisplatin-resistant non-small lung cancer cells.
Authors: Li Y, Hu T, Chen T, Yang T, Ren H, Chen M Abstract A major common medical treatment for lung carcinoma is cisplatin (DDP)-based therapy. However, the development or existence of chemoresistance frequently blocks its effectiveness. Currently, autophagy is recognised as a potential anticancer strategy, although there is controversy over its role in the development of cancer. In lung carcinoma, no studies of autophagy induced by FTY720, a sphingosine 1-phosphate analog and a novel immunosuppressant drug, have been published, while apoptosis has been shown to be induced by FTY720 in several cancer cell lines. ...
Source: Oncology Reports - December 6, 2017 Category: Cancer & Oncology Tags: Oncol Rep Source Type: research

Placenta-specific protein 1 promotes cell proliferation and invasion in non-small cell lung cancer.
Authors: Yang L, Zha TQ, He X, Chen L, Zhu Q, Wu WB, Nie FQ, Wang Q, Zang CS, Zhang ML, He J, Li W, Jiang W, Lu KH Abstract Pulmonary carcinoma-associated proteins have emerged as crucial players in governing fundamental biological processes such as cell proliferation, apoptosis and metastasis in human cancers. Placenta-specific protein 1 (PLAC1) is a cancer-related protein, which is activated and upregulated in a variety of malignant tissues, including prostate cancer, gastric adenocarcinoma, colorectal, epithelial ovarian and breast cancer. However, its biological role and clinical significance in non-small cell...
Source: Oncology Reports - November 16, 2017 Category: Cancer & Oncology Tags: Oncol Rep Source Type: research

Torilis japonica extract fraction compound, EGFR-targeted inhibition of cancer abnormal metastasis in A549 lung cancer cells.
In this study, we investigated the inhibitory effect of Torilis japonica extract (TJE) major fraction compound in A549 lung cancer cells by inhibiting EGFR activity. We confirmed that inhibitory effect of TJE on the abnormal metastasis using invasion assay and 3D cell culture method, as well as the inhibition of EGFR signaling pathway, co-binding with Stat3 and dimer formation for translocation to the nucleus. We confirmed the EGFR targets inhibition of TJE when compared with EGFR knockdown group using siRNA transfection. The CAM assay confirmed once again the efficacy of the TJE. We suggest that TJE is a new potential r...
Source: Oncology Reports - July 6, 2017 Category: Cancer & Oncology Tags: Oncol Rep Source Type: research